Eli Lilly & Co $59.96

up +0.54


16/4/2014 06:40 PM  |  NYSE : LLY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get LLY Trend Analysis - it has underperformed the S&P 500 by 13%

Partner Headlines

  1. Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings

    Benzinga
  2. Lilly, Takeda must pay $9 bil

    IBD
  3. Ethical Drug Stocks Are Struggling

    IBD
  4. UPDATE: BMO Capital Upgrades Eli Lilly

    Benzinga
  5. Takeda, Lilly to 'Vigorously Challenge' Actos Ruling

    FoxBusiness
  6. Benzinga's Top Upgrades

    Benzinga
  7. Takeda Responds to $6B Verdict in Diabetes Drug Case

    Benzinga
  8. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest ...

    Benzinga
  9. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  10. Market Wrap For April 3: Markets Winning Streak Fails To Extend To Five ...

    Benzinga
  11. Wide Moat Stocks: Protection In A Correction

    YCharts
  12. UPDATE: Cowen & Company Upgrades Eli Lilly

    Benzinga
  13. Benzinga's Top Upgrades

    Benzinga
  14. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  15. Lilly Expands Generic Deal With Prasco

    FoxBusiness
  16. UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta ...

    Benzinga
  17. Merck Snags Baxter Executive As CFO

    FoxBusiness
  18. Box, Online Storage Service Provider, Files For IPO

    IBD
  19. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  20. Forest Laboratories' Recovery

    GuruFocus
  21. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  22. Pharma Patent Cliff: Why Worst Seems Over

    YCharts
  23. Elanco Announces Agreement to Acquire Lohmann Animal Health; Lowers FY ...

    Benzinga
  24. Actavis Q4 Beats Street; Guidance Affirmed For Now

    IBD
  25. Eli Lilly up on lung cancer trial

    IBD
  26. Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak

    Benzinga
  27. Lilly Drug Ramucirumab Boosts Lung Cancer Survival

    IBD
  28. Stocks Stage Quiet, Mixed Open; Eli Lilly Up, U.S. Steel Tanks

    IBD
  29. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  30. #PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over ...

    Benzinga
  31. Eli Lilly

    IBD
  32. Market Wrap For January 30: Markets Focus on Good News

    Benzinga
  33. Lilly's Cymbalta to Trigger 'Severe' Sales Slide

    FoxBusiness
  34. UPDATE: Eli Lilly Posts Drop In Q4 Profit

    Benzinga
  35. #PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By Further $1 ...

    Benzinga
  36. Tug Of War In Ariad Pharmaceuticals

    Benzinga
  37. Benzinga's M&A Chatter for Monday January 27, 2014

    Benzinga
  38. Income + Value Investing: YCharts Sector Report

    YCharts
  39. Benzinga Weekly Preview: Tech Sector To Steal The Spotlight

    Benzinga
  40. Ariad Shares Continue to Surge Amidst Buyout Rumors

    Benzinga
  41. Is The Market On Drugs?

    Benzinga
  42. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is

    GuruFocus
  43. Wide Moat Stocks Against Two Value Systems

    YCharts
  44. Biogen, Celgene Lead 5 Top Large-Cap Drugmakers

    IBD
  45. Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics ...

    Benzinga
  46. Bulls Charge the Street: S&P Snaps 3-Day Losing Streak

    FoxBusiness
  47. Celgene Gets Good News On Two Cancer Drugs; Stock Up

    IBD
  48. Wall Street Climbs on Trade Data, Yellen Optimism

    FoxBusiness
  49. Eli Lilly Projects In-Line '14 Profit Slump

    FoxBusiness
  50. Stock Futures Jump Amid Fed Optimism

    FoxBusiness
Trading Center